Parkman Healthcare Partners LLC lifted its position in shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT – Get Rating) by 4.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,557 shares of the technology company's stock after acquiring an additional 1,266 shares during the period. Parkman Healthcare Partners LLC owned about 0.64% of Opiant Pharmaceuticals worth $697,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. increased its position in Opiant Pharmaceuticals by 10.7% in the first quarter. JPMorgan Chase & Co. now owns 7,466 shares of the technology company's stock worth $160,000 after buying an additional 723 shares during the period. Essex Investment Management Co. LLC grew its holdings in Opiant Pharmaceuticals by 2.5% during the first quarter. Essex Investment Management Co. LLC now owns 32,040 shares of the technology company's stock worth $686,000 after acquiring an additional 777 shares during the period. Advisor Group Holdings Inc. increased its stake in Opiant Pharmaceuticals by 28.5% in the 4th quarter. Advisor Group Holdings Inc. now owns 8,125 shares of the technology company's stock worth $273,000 after purchasing an additional 1,800 shares in the last quarter. Apis Capital Advisors LLC increased its stake in Opiant Pharmaceuticals by 1.8% in the 1st quarter. Apis Capital Advisors LLC now owns 112,000 shares of the technology company's stock worth $2,399,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Opiant Pharmaceuticals by 11.6% in the 4th quarter. Acadian Asset Management LLC now owns 71,916 shares of the technology company's stock worth $2,417,000 after purchasing an additional 7,475 shares in the last quarter. 36.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, TheStreet cut Opiant Pharmaceuticals from a "c" rating to a "d+" rating in a research note on Tuesday, May 31st.

Opiant Pharmaceuticals Trading Up 4.2 %

Insiders Place Their Bets

In other Opiant Pharmaceuticals news, Director Craig A. Collard acquired 4,037 shares of the firm's stock in a transaction on Monday, June 13th. The stock was purchased at an average cost of $10.94 per share, for a total transaction of $44,164.78. Following the transaction, the director now owns 53,822 shares of the company's stock, valued at approximately $588,812.68. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 6,327 shares of company stock worth $69,794. 25.15% of the stock is currently owned by company insiders.

About Opiant Pharmaceuticals

(Get Rating)

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.

Read More

• Get a free copy of the StockNews.com research report on Opiant Pharmaceuticals (OPNT)
• Prepare For A Record-Setting Quarter For Cyber Security Stocks
• The Auto Market Is Slowly Recovering, These Stocks May Outperform
• Is DocuSign On The Verge Of A Major Reversal?
• Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
• Are These Green Energy Companies Right For Your Portfolio?

Want to see what other hedge funds are holding OPNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT – Get Rating).

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.